What is the recommended mifepristone‑misoprostol regimen for medical termination of pregnancy (MTP) up to 10 weeks gestation in a patient without contraindications?

Mifepristone-Misoprostol Regimen for Medical Termination of Pregnancy (MTP)

For medical termination of pregnancy up to 10 weeks (70 days) gestation, administer mifepristone 200 mg orally followed 24-48 hours later by misoprostol 800 mcg vaginally (or buccally/sublingually if preferred), with vaginal administration offering fewer adverse effects.

Evidence-Based Dosing Protocol

Mifepristone Administration

• Dose: 200 mg orally (single dose)
• Timing: Day 1 of treatment
• Key point: The previously used 600 mg dose has been replaced by 200 mg, which is equally effective with less medication exposure 1

Misoprostol Administration

• Dose: 800 mcg
• Route: Vaginal administration is preferred (buccal or sublingual are alternatives)
• Timing: 24-48 hours after mifepristone
• Critical: The 800 mcg dose is superior to 400 mcg—studies demonstrate that 400 mcg has significantly higher failure rates (9.5% vs 5.8% incomplete abortion, P<0.01) and more continuing pregnancies 1

Route Selection Considerations

Vaginal misoprostol should be the first-line route because:

• Equivalent efficacy to sublingual/buccal routes (no statistical difference in complete abortion rates, P=0.47) 1
• Significantly fewer adverse effects including less nausea, vomiting, and diarrhea compared to oral/sublingual routes 2, 1
• Better patient tolerability overall

Buccal or sublingual alternatives are acceptable when:

• Patient preference for self-administration at home
• Cultural or personal preference against vaginal administration
• Similar efficacy but expect more gastrointestinal side effects

Timing Interval: Critical Decision Point

Standard 24-48 Hour Interval (Recommended)

This is the evidence-based standard you should use:

• Complete abortion rate: 96.9% 3
• Patient satisfaction: 81.1% 4
• Lower risk of continuing pregnancy: 2.8% 4

Simultaneous Administration (NOT Recommended)

Do not use concurrent administration despite potential convenience:

• Significantly lower success rate: 68.8% vs 84.3% (P=0.007) 4
• Higher continuing pregnancy rate: 13.4% vs 2.8% (P=0.004) 4
• Lower patient satisfaction: 63.6% vs 81.1% (P=0.04) 4
• Recent 2025 RCT definitively shows inferiority 4

Gestational Age Stratification

Up to 49 Days (7 Weeks)

• Success rate: 92% complete abortion 5
• Most effective window for medical abortion
• Lowest complication rates

50-56 Days (7-8 Weeks)

• Success rate: 83% complete abortion 5
• Still highly effective
• Slightly increased adverse effects

57-63 Days (8-9 Weeks)

• Success rate: 77% complete abortion 5
• Higher failure rate, particularly ongoing pregnancies (9% vs 1% at <49 days, P<0.001) 5
• Increased need for surgical intervention

64-70 Days (9-10 Weeks)

• FDA-approved extension to 70 days 6
• Expect lower success rates than earlier gestations
• Counsel patients about higher likelihood of requiring additional intervention

Follow-Up Protocol

Timing

• First assessment: 7±1 days after mifepristone administration 3
• Final assessment: Day 15 or approximately 2 weeks post-treatment 5, 4

What to Assess

• Transvaginal ultrasound to confirm complete abortion
• Clinical examination for ongoing pregnancy signs
• Hemoglobin if heavy bleeding reported
• If abortion incomplete: offer second misoprostol dose (800 mcg) and reassess in 1 week

Failure Criteria Requiring Intervention

• Ongoing pregnancy with cardiac activity
• Incomplete abortion with heavy bleeding
• Patient request for surgical completion
• Retained products causing symptoms beyond 2 weeks

Expected Adverse Effects (Counsel Patients)

Common (Dose and Route Dependent)

• Abdominal pain: Universal, increases with gestational age
• Vaginal bleeding: Expected, heavier than normal menses
• Nausea/vomiting: More common with oral/sublingual routes (57% oral vs 45% vaginal, P=0.005) 7
• Diarrhea: More common with oral/sublingual routes (36% oral vs 26% vaginal, P=0.011) 7

Timing of Expulsion

• 49% complete within 4 hours of misoprostol 5
• 75% complete within 24 hours 5
• Nearly all complete by 48 hours

Serious Complications (Rare, ~2-4%)

• Hospitalization requirement
• Need for IV fluids
• Emergency surgical intervention
• Risk increases from 2% at ≤49 days to 4% at 50-63 days (P=0.008) 5

Critical Pitfalls to Avoid

1. Do NOT use 400 mcg misoprostol dose—this is inadequate and increases failure rates by nearly 4% 1

2. Do NOT administer medications simultaneously—recent high-quality evidence shows this reduces efficacy by 15-20% 4

3. Do NOT skip the 24-hour interval—intervals <12 hours significantly compromise effectiveness 8

4. Do NOT use oral misoprostol as first choice—vaginal route has equivalent efficacy with better tolerability 2, 1

5. Do NOT extend beyond 70 days gestation with this regimen—efficacy drops substantially and second-trimester protocols are required

Patient Satisfaction

Overall satisfaction rates are high (94%) when using the evidence-based protocol 1. Route preference is split approximately 50/50 between vaginal and sublingual, so offer patient choice between these routes while emphasizing vaginal administration has fewer side effects 1.